RP | 2325-51-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: RP
• 英文别名: 1-[2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carboxylic acid
• CAS: 2325-51-1
• 化学式: C₁₁H₂₁N₅O₃
• 分子量: 271.32
• InChiKey: LQJAALCCPOTJGB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.3
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  148
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  RP 、 (2,4,5-trichlorophenyl) (2R)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoate 生成 1-[5-(diaminomethylideneamino)-2-[[(2R)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]amino]pentanoyl]pyrrolidine-2-carboxylic acid
  参考文献：
  名称：

  REISS. MANN, SIEGMUND;AROLD, HELMUT;SCHWUCHOW, CAROLA;SCHUBERT, HARALD;CR+

  摘要：

  DOI：

文献信息

• Nutrient compositions containing peptides
  申请人：CLINTEC NUTRITION COMPANY

  公开号：EP0457314A1

  公开（公告）日：1991-11-21

  Nutrient compositions comprise an aqueous solution of at least one dipeptide with an N-terminal amino acid selected from glutamine, aspargine, tyrosine, tryptophan, and aspargine. The C-terminal amino acid is alanine, glycine, tryptophan, arginine, proline or serine. The nutritional compositions contain from about 0.1 to 25.0 percent by weight of oligopeptides, preferably about 0.5 to 5.0 percent by weight.

  营养组合物包含至少一种二肽的水溶液，其 N 端氨基酸选自谷氨酰胺、天门冬氨酸、酪氨酸、色氨酸和天门冬氨酸。 C 端氨基酸为丙氨酸、甘氨酸、色氨酸、精氨酸、脯氨酸或丝氨酸。营养组合物含有约 0.1%至 25.0%（按重量计）的低聚肽，最好是约 0.5%至 5.0%（按重量计）。
• Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment
  申请人：Metabolon, Inc.

  公开号：US10267777B2

  公开（公告）日：2019-04-23

  Methods are described herein for small molecule biochemical profiling of an individual subject for diagnosis of a disease or disorder, facilitating diagnosis of a disease or disorder, and/or identifying an increased risk of developing a disease or disorder in the individual subject. Aberrant levels of small molecules present in a sample from an individual subject are identified and diagnostic information relevant to the individual subject is obtained based on the identified aberrant levels. The obtained diagnostic information includes one or more of an identification of at least one biochemical pathway associated with the identified subset of the small molecules having aberrant levels, an identification at least one disease or disorder associated with the identified subset of the small molecules having aberrant levels, and an identification of at least one recommended follow up test associated with the identified subset of the small molecules having aberrant levels.

  本文描述了对个体受试者进行小分子生化分析的方法，以诊断疾病或失调，促进疾病或失调的诊断，和/或确定个体受试者罹患疾病或失调的风险增加。确定个体受试者样本中存在的小分子的异常水平，并根据确定的异常水平获得与个体受试者相关的诊断信息。所获得的诊断信息包括：至少一个生化途径的鉴定，该生化途径与所鉴定的具有异常水平的小分子子集相关；至少一种疾病或紊乱的鉴定，该疾病或紊乱与所鉴定的具有异常水平的小分子子集相关；至少一种推荐的后续检测的鉴定，该检测与所鉴定的具有异常水平的小分子子集相关。
• Peptide structures useful for competitive modulation of dipeptidyl peptidase IV catalysis
  申请人：——

  公开号：US20030135023A1

  公开（公告）日：2003-07-17

  This invention involves a compound represented by the general formula (I): 1 and pharmaceutically acceptable salts thereof, wherein A is any amino acid except a D-amino acid; B is an amino acid selected from Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid and pipecolic acid, C is any amino acid except Pro, Hyp, acetidine-(2)-carboxylic acid, pipecolic acid and except N-alkylated amino acids, e.g. N-methyl valine and sarcosine, D is any amino acid or missing, and E is any amino acid or missing; or wherein C is any amino acid except Pro, Hyp, acetidine-(2)-carboxylic acid, pipecolic acid, except N-alkylated amino acids, e.g. N-methyl valine and sarcosine and except a D-amino acid, D is an amino acid selected from Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid and pipecolic acid, and E is any amino acid except Pro, Hyp, acetidine-(2)-carboxylic acid, pipecolic acid and except N-alkylated amino acids, e.g. N-methyl valine and sarcosine and methods of manufacture and use.

  本发明涉及一种由通式(I)表示的化合物： 1 及其药学上可接受的盐类、 其中 A 是除 D-氨基酸以外的任何氨基酸； B 是选自 Pro、Ala、Ser、Gly、Hyp、乙脒-(2)-羧酸和哌啶醇酸的氨基酸、 C 是任何氨基酸，但 Pro、Hyp、乙脒-(2)-羧酸、哌啶醇酸和 N-烷基化氨基酸（如 N-甲基缬氨酸和肌氨酸）除外、 D 是任何氨基酸或缺如，以及 E 为任何氨基酸或缺失； 或 其中 C 是任何氨基酸，但 Pro、Hyp、乙脒-(2)-羧酸、哌啶醇酸除外，N-烷基化氨基酸（如 N-甲基缬氨酸和肌氨酸）除外，D-氨基酸除外、 D 是选自 Pro、Ala、Ser、Gly、Hyp、乙脒-(2)-羧酸和哌啶酸的氨基酸，以及 E 是除 Pro、Hyp、乙脒-(2)-羧酸、哌啶醇酸和 N-烷基化氨基酸（如 N-甲基缬氨酸和肌氨酸）以外的任何氨基酸，以及制造和使用方法。
• Fragmentation-based methods and systems for de novo sequencing
  申请人：Boecker Sebastian

  公开号：US20050009053A1

  公开（公告）日：2005-01-13

  Methods and systems, particularly mass spectrometric methods and systems, for the analysis and sequencing of biomolecules, particularly nucleic acids, by fragmentation are provided.

  提供了通过碎片分析生物大分子（尤其是核酸）和测序的方法和系统，特别是质谱方法和系统。
• Fragmentation-based methods and systems for sequence variation detection and discovery
  申请人：Boom van den Dirk

  公开号：US20050112590A1

  公开（公告）日：2005-05-26

  Fragmentation-based methods and systems, particularly mass spectrometric methods and systems, for the analysis of sequence variations are provided.

  提供了用于分析序列变异的基于碎片的方法和系统，特别是质谱方法和系统。